145 related articles for article (PubMed ID: 12154391)
1. The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?
Teti A; Migliaccio S; Baron R
Calcif Tissue Int; 2002 Oct; 71(4):293-9. PubMed ID: 12154391
[TBL] [Abstract][Full Text] [Related]
2. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
Guise TA; Mohammad KS; Clines G; Stebbins EG; Wong DH; Higgins LS; Vessella R; Corey E; Padalecki S; Suva L; Chirgwin JM
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6213s-6216s. PubMed ID: 17062703
[TBL] [Abstract][Full Text] [Related]
3. Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
Min Y; Ren X; Vaught DB; Chen J; Donnelly E; Lynch CC; Lin PC
Cancer Res; 2010 Apr; 70(7):2819-28. PubMed ID: 20233869
[TBL] [Abstract][Full Text] [Related]
4. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
Zhao Y; Bachelier R; Treilleux I; Pujuguet P; Peyruchaud O; Baron R; Clément-Lacroix P; Clézardin P
Cancer Res; 2007 Jun; 67(12):5821-30. PubMed ID: 17575150
[TBL] [Abstract][Full Text] [Related]
5. Evidence that activation of ASIC1a by acidosis increases osteoclast migration and adhesion by modulating integrin/Pyk2/Src signaling pathway.
Li X; Ye JX; Xu MH; Zhao MD; Yuan FL
Osteoporos Int; 2017 Jul; 28(7):2221-2231. PubMed ID: 28462470
[TBL] [Abstract][Full Text] [Related]
6. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer metastasis to the bone: mechanisms of bone loss.
Chen YC; Sosnoski DM; Mastro AM
Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
10. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
11. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
[TBL] [Abstract][Full Text] [Related]
12. Effects of cilengitide in osteoclast maturation and behavior.
Chillà A; Bianconi D; Geetha N; Dorda A; Poettler M; Unseld M; Sykoutri D; Redlich K; Zielinski CC; Prager GW
Exp Cell Res; 2015 Sep; 337(1):68-75. PubMed ID: 26209605
[TBL] [Abstract][Full Text] [Related]
13. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.
Wadas TJ; Deng H; Sprague JE; Zheleznyak A; Weilbaecher KN; Anderson CJ
J Nucl Med; 2009 Nov; 50(11):1873-80. PubMed ID: 19875645
[TBL] [Abstract][Full Text] [Related]
14. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.
Sadanandam A; Futakuchi M; Lyssiotis CA; Gibb WJ; Singh RK
BMC Cancer; 2011 Jul; 11():304. PubMed ID: 21774828
[TBL] [Abstract][Full Text] [Related]
15. The type II collagen N-propeptide, PIIBNP, inhibits cell survival and bone resorption of osteoclasts via integrin-mediated signaling.
Hayashi S; Wang Z; Bryan J; Kobayashi C; Faccio R; Sandell LJ
Bone; 2011 Oct; 49(4):644-52. PubMed ID: 21708300
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
17. Osteolytic metastasis in breast cancer: effective prevention strategies.
Mandal CC
Expert Rev Anticancer Ther; 2020 Sep; 20(9):797-811. PubMed ID: 32772585
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.
Das S; Samant RS; Shevde LA
J Biol Chem; 2011 Mar; 286(11):9612-22. PubMed ID: 21169638
[TBL] [Abstract][Full Text] [Related]
19. Blockade of XCL1/Lymphotactin Ameliorates Severity of Periprosthetic Osteolysis Triggered by Polyethylene-Particles.
Tian Y; Terkawi MA; Onodera T; Alhasan H; Matsumae G; Takahashi D; Hamasaki M; Ebata T; Aly MK; Kida H; Shimizu T; Uetsuki K; Kadoya K; Iwasaki N
Front Immunol; 2020; 11():1720. PubMed ID: 32849609
[TBL] [Abstract][Full Text] [Related]
20. Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.
Kawatani M; Osada H
Cancer Sci; 2009 Nov; 100(11):1999-2005. PubMed ID: 19673888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
